Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medpace Holdings's Revenue for the
three
months ended in Jun. 2026 was MXN12,342 Mil. Medpace Holdings's average Accounts Receivable for the
three
months ended in Jun. 2026 was MXN7,009 Mil.
Hence, Medpace Holdings's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.76.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medpace Holdings Receivables Turnover Related Terms
Medpace Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MEDP vs ICLR, RVTY, CRL: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEX:MEDP) has a Receivables Turnover of 1.76 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medpace Holdings and its competitors. According to the industry distribution chart, Medpace Holdings ranks #55 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 27.2%.
Is Medpace Holdings' Receivables Turnover too high?
Medpace Holdings' current Receivables Turnover is 1.76. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Medpace Holdings' value of 1.76 is 67.3% below this industry median. Based on the distribution chart, Medpace Holdings ranks #55 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Receivables Turnover compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #55 out of 202 companies for Receivables Turnover. This puts Medpace Holdings in the upper half of its industry. The industry median Receivables Turnover is 5.38. Medpace Holdings' value of 1.76 is 67.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current Receivables Turnover of 1.76 is 67.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Receivables Turnover is 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current Receivables Turnover of 1.76. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current Receivables Turnover is 1.76 and 67.3% below the Medical Diagnostics & Research industry median of 5.38. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current Receivables Turnover is 1.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
Receivables Turnover: 1.76
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
Industry Position: 67.3% below the Medical Diagnostics & Research median (#55 of 202)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for MEX:MEDP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
